2）リウマチ性疾患治療の発展と今後の課題
Saved in:
| Published in | 日本内科学会雑誌 Vol. 111; no. 9; pp. 1804 - 1810 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人 日本内科学会
10.09.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-5384 1883-2083 |
| DOI | 10.2169/naika.111.1804 |
Cover
| Author | 山岡, 邦宏 |
|---|---|
| Author_xml | – sequence: 1 fullname: 山岡, 邦宏 organization: 北里大学膠原病・感染内科学 |
| BookMark | eNo9kD9LA0EUxBeJYIxp_RYX993u3r2z0-A_CNhofby73dOLMcpdGjuTVIa0CmkEEVRSCKY0ki9zJtHKr2CMYjMDMzDwm2WWq5_VDWOrwEs2ON5aneITKgFACZDLBZYHRGHZHEWO5Tm3wVIC5RIrpmkccCkchSBknq3bX29XWbuftR6y9m3Wbk4uH6c3o0nrfjIYTnutrPk87b2OX66z5tP7sDMedWfJR3_wedddYYsR1VJT_PMCO9zeOijvWpX9nb3yRsWqgkLPUkiBBK0MR60CGRGFSnClw9BwodHhLniBbQwIQiltJBWCa1SgEV0dOVoU2ObvbjVt0JHxz5P4lJILn5JGHNaMP0f3Z-i-N9efA_7L8JgSv0riG6ebar4 |
| ContentType | Journal Article |
| Copyright | 2022 一般社団法人 日本内科学会 |
| Copyright_xml | – notice: 2022 一般社団法人 日本内科学会 |
| DOI | 10.2169/naika.111.1804 |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1883-2083 |
| EndPage | 1810 |
| ExternalDocumentID | article_naika_111_9_111_1804_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS DIK F5P JSF OK1 RJT |
| ID | FETCH-LOGICAL-j1589-58ab41d5e08d5b4faac5305dcce03d860719b2ee13a84428a5c17e5bd887df6d3 |
| ISSN | 0021-5384 |
| IngestDate | Wed Sep 03 06:30:54 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 9 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j1589-58ab41d5e08d5b4faac5305dcce03d860719b2ee13a84428a5c17e5bd887df6d3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/naika/111/9/111_1804/_article/-char/ja |
| PageCount | 7 |
| ParticipantIDs | jstage_primary_article_naika_111_9_111_1804_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2022/09/10 |
| PublicationDateYYYYMMDD | 2022-09-10 |
| PublicationDate_xml | – month: 09 year: 2022 text: 2022/09/10 day: 10 |
| PublicationDecade | 2020 |
| PublicationTitle | 日本内科学会雑誌 |
| PublicationTitleAlternate | 日内会誌 |
| PublicationYear | 2022 |
| Publisher | 一般社団法人 日本内科学会 |
| Publisher_xml | – name: 一般社団法人 日本内科学会 |
| References | 11) Tanaka Y, et al: Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Annals of the rheumatic diseases 69 (7): 1286-1291, 2010. 9) Ohara Y, et al: Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. The Journal of rheumatology 42 (8): 1439-1442, 2015. 3) Weinblatt ME, et al: Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis care & research 65 (3): 362-371, 2013. 14) Takeuchi T, et al: Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Annals of the rheumatic diseases 78 (2): 171-178, 2019. 2) Gabay C, et al: Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381 (9877): 1541-1550, 2013. 6) Harigai M, et al: Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Modern rheumatology/the Japan Rheumatism Association 26 (4): 491-498, 2016. 8) Tanaka Y: Psoriatic arthritis in Japan: difference in clinical features and approach to precision medicine. Clinical and experimental rheumatology 34 (4 Suppl 98): 49-52, 2016. 15) Dagnew AF, et al: Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford) 60 (3): 1226-1233, 2020. 4) Fernandez-Diaz C, et al: Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Seminars in arthritis and rheumatism 48 (1): 22-27, 2018. 1) Smolen JS, et al: Rheumatoid arthritis. Nat Rev Dis Primers 4: 18001, 2018. 10) Danve A, Deodhar A: Treatment of axial spondyloarthritis: an update. Nature reviews Rheumatology 18 (4): 205-216, 2022. 7) Takeuchi T, et al: Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Annals of the rheumatic diseases 78 (7): 899-907, 2019. 5) Nakashita T, et al: Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients. Respir Investig 54 (5): 376-379, 2016. 12) Schett G, et al: Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Annals of the rheumatic diseases 75 (8): 1428-1437, 2016. 13) Kubo S, et al: Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology 56 (8): 1293-1301, 2017. |
| References_xml | – reference: 14) Takeuchi T, et al: Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Annals of the rheumatic diseases 78 (2): 171-178, 2019. – reference: 2) Gabay C, et al: Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381 (9877): 1541-1550, 2013. – reference: 3) Weinblatt ME, et al: Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis care & research 65 (3): 362-371, 2013. – reference: 15) Dagnew AF, et al: Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford) 60 (3): 1226-1233, 2020. – reference: 9) Ohara Y, et al: Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. The Journal of rheumatology 42 (8): 1439-1442, 2015. – reference: 5) Nakashita T, et al: Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients. Respir Investig 54 (5): 376-379, 2016. – reference: 1) Smolen JS, et al: Rheumatoid arthritis. Nat Rev Dis Primers 4: 18001, 2018. – reference: 12) Schett G, et al: Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Annals of the rheumatic diseases 75 (8): 1428-1437, 2016. – reference: 11) Tanaka Y, et al: Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Annals of the rheumatic diseases 69 (7): 1286-1291, 2010. – reference: 13) Kubo S, et al: Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology 56 (8): 1293-1301, 2017. – reference: 10) Danve A, Deodhar A: Treatment of axial spondyloarthritis: an update. Nature reviews Rheumatology 18 (4): 205-216, 2022. – reference: 8) Tanaka Y: Psoriatic arthritis in Japan: difference in clinical features and approach to precision medicine. Clinical and experimental rheumatology 34 (4 Suppl 98): 49-52, 2016. – reference: 4) Fernandez-Diaz C, et al: Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Seminars in arthritis and rheumatism 48 (1): 22-27, 2018. – reference: 6) Harigai M, et al: Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Modern rheumatology/the Japan Rheumatism Association 26 (4): 491-498, 2016. – reference: 7) Takeuchi T, et al: Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Annals of the rheumatic diseases 78 (7): 899-907, 2019. |
| SSID | ssib043658134 ssj0066765 ssib002821954 ssib005879745 ssib007485360 ssib058493862 ssib000940260 ssib002484664 |
| Score | 2.3073478 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 1804 |
| SubjectTerms | Janus kinase 生物学的製剤 関節リウマチ |
| Title | 2）リウマチ性疾患治療の発展と今後の課題 |
| URI | https://www.jstage.jst.go.jp/article/naika/111/9/111_1804/_article/-char/ja |
| Volume | 111 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日本内科学会雑誌, 2022/09/10, Vol.111(9), pp.1804-1810 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1NaxNBdKkVxIv4id_04Jxka2ZnZveNnnbjhqJUKLTQW9jPQw6pSHrxZJKT0qtCL4IIKj0I9milf2Ztoif_gu_NbpIN9GDrZRnezHvzPiZ57-3OvLGseynmDHkuuZ0kbsOWKsvtKKWv7LlQkIhc5ebr-eozd2VDPtlUmwtn1mq7lrZ78XLy8thzJaexKsLQrnRK9gSWnRJFALbRvvhEC-Pzn2zssLDFgiYDzULBQDDfNw2H-W4F0WHVAM5Cl_Y1-B4LPaZdFoQGgoMFNQKHBYHp0gQMDYofVpAAKSsWcKbVpAtYKAkFyq6QQbOGBcQM0gw18zl21aNgmk57zFem0WR-kygAMqNoOuRQc4L4j40gkmTUPpHSgekyxGH6grdiLTBIOCdOiCuHxleqUMQStOqvODA7pisaGtNFaeYB0hCSBzBMIS_S6EnRzJWehNGBJJUE_v3TyVJ3Fg630R-U7zuy0j8ACFyC5d07UwdSuYvyl6Jr7oBDQ9ZCC4ymGse5LYe7VPW1S4fGyIctz_DmSoFXC61tBlLu1tbmScPbk046rdfuYMpw1vE8s3Ph6Vot4taSqsjVIjSYu2AAM3BerxCowNP1CxE8ifHdDF8KjGD5rMIghrNagDut4EY7qMtLRCpdlnVTSeAH8-JiBNjBfGiyl9KEd-sXrQtVXrbkl-JdshY60WXr3Gq18-SK9dD58-N1MdwrBp-K4fti2B-9-jx-dzgafBztH4x3B0X_63j3-9G3t0X_y8-DN0eHOwj5tbf_-8POVWujFa43V-zq3hG7wxVoW0EUS56qrAGpimUeRYlCt5gmdLdeClSRUcdOlnERgcT0PVIJ9zIVp-iw09xNxTVrsbvVza5bS9pNIo0xd5oKTzqRil0lI_wL5C6AG_H4hvWolLr9vCwu0z6JjW_-F_Yt6_zsx3bbWuy92M7uYITdi--aNfMXUeelVg |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=2%EF%BC%89%E3%83%AA%E3%82%A6%E3%83%9E%E3%83%81%E6%80%A7%E7%96%BE%E6%82%A3%E6%B2%BB%E7%99%82%E3%81%AE%E7%99%BA%E5%B1%95%E3%81%A8%E4%BB%8A%E5%BE%8C%E3%81%AE%E8%AA%B2%E9%A1%8C&rft.jtitle=%E6%97%A5%E6%9C%AC%E5%86%85%E7%A7%91%E5%AD%A6%E4%BC%9A%E9%9B%91%E8%AA%8C&rft.au=%E5%B1%B1%E5%B2%A1%2C+%E9%82%A6%E5%AE%8F&rft.date=2022-09-10&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E5%86%85%E7%A7%91%E5%AD%A6%E4%BC%9A&rft.issn=0021-5384&rft.eissn=1883-2083&rft.volume=111&rft.issue=9&rft.spage=1804&rft.epage=1810&rft_id=info:doi/10.2169%2Fnaika.111.1804&rft.externalDocID=article_naika_111_9_111_1804_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-5384&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-5384&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-5384&client=summon |